These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32185726)

  • 1. Therapeutic Development of Immune Checkpoint Inhibitors.
    Wang J; Yang T; Xu J
    Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Resistance to Checkpoint Blockade Therapy.
    Shi H; Lan J; Yang J
    Adv Exp Med Biol; 2020; 1248():83-117. PubMed ID: 32185708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of New Immune Checkpoints: Family Grows Up.
    Kong X
    Adv Exp Med Biol; 2020; 1248():61-82. PubMed ID: 32185707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation: A Fast Switch For Checkpoint Signaling.
    Wang Y; Wang P; Xu J
    Adv Exp Med Biol; 2020; 1248():347-398. PubMed ID: 32185718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery.
    Ding S; Li S; Zhang S; Li Y
    Adv Exp Med Biol; 2020; 1248():227-250. PubMed ID: 32185713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
    Long L; Zhao C; Ozarina M; Zhao X; Yang J; Chen H
    Clin Drug Investig; 2019 Apr; 39(4):341-353. PubMed ID: 30778885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
    Baksh K; Weber J
    Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.
    Krueger J; Rudd CE; Taylor A
    Semin Immunol; 2019 Apr; 42():101295. PubMed ID: 31604533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.